Company Overview
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -33.3%, profit CAGR -12.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -12.81% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -21.75% |
| 6 Months: | -12.20% |
| 3 Months: | -13.23% |
| 1 Month: | -3.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -33.3% CAGR over 5 years.
- Earnings shrank at -12.8% CAGR over 5 years.
- Trading 36.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XBIT XBiotech Inc. | 2.23 | -1.70 | $67.99M | 0.00% | -31.81% | -25.93% | -33.33% | -12.81% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 13.55M | 6.34M | 6.05M | 29.75M | 6.27M |
| Operating Income | -13.55M | -6.34M | -6.05M | -29.75M | -6.27M |
| EBITDA | -10.32M | -1.29M | -5.48M | -26.44M | -5.12M |
| Interest Expense | 88.00K | 0 | 0 | 0 | 0 |
| Pretax Income | -10.86M | -1.73M | -5.91M | -26.82M | -5.46M |
| Tax Provision | 29.00K | 28.00K | 102.00K | 76.00K | 49.00K |
| Net Income | -10.88M | -1.76M | -6.01M | -26.89M | -5.50M |
| Diluted EPS | -0.36 | -0.06 | -0.20 | - | -0.18 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 4.01M | 0 | 0 | 0 |
| Cost of Revenue | 5.82M | 651.00K | 0 | - | - |
| Gross Profit | 12.57M | 3.36M | 0 | - | - |
| Operating Expenses | - | 37.85M | 37.51M | 42.47M | 55.69M |
| Operating Income | - | -34.49M | -37.51M | -42.47M | -55.69M |
| EBITDA | - | -31.88M | -22.57M | -36.01M | -43.53M |
| Interest Expense | - | - | 0 | 807.00K | 88.00K |
| Pretax Income | - | -33.59M | -24.31M | -38.56M | -45.30M |
| Tax Provision | - | -688.00K | 244.00K | -32.00K | 235.00K |
| Net Income | - | -32.90M | -24.56M | -38.53M | -45.54M |
| Diluted EPS | - | -1.08 | -0.81 | -1.26 | -1.49 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 246.10M | 226.62M | 199.09M | 150.08M |
| Current Assets | - | 219.84M | 201.72M | 174.57M | 126.95M |
| Cash & Equivalents | - | 157.31M | 200.02M | 172.68M | 125.55M |
| Inventory | - | - | - | - | - |
| Receivables | 0 | - | - | - | - |
| Total Liabilities | - | 5.70M | 7.77M | 16.82M | 9.73M |
| Current Liabilities | - | 4.07M | 6.10M | 15.11M | 7.93M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | 10.25M | - |
| Total Equity | - | 240.40M | 218.85M | 182.27M | 140.35M |
| Shares Outstanding | - | 30.44M | 30.44M | 30.49M | 30.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.82M | -18.73M | -30.96M | -39.92M |
| Investing Cash Flow | - | -63.89M | 61.50M | -1.30M | -289.00K |
| Financing Cash Flow | - | 0 | -9.00K | 10.45M | -10.25M |
| Capital Expenditure | - | -585.00K | -362.00K | -1.30M | -289.00K |
| Free Cash Flow | - | -15.41M | -19.09M | -32.27M | -40.21M |
| Net Change in Cash | - | -78.72M | 42.76M | -21.82M | -50.46M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 83.8% | - | - | - |
| Operating Margin % | - | -860.1% | - | - | - |
| Net Margin % | - | -820.4% | - | - | - |
| ROE % | - | -13.7% | -11.2% | -21.1% | -32.4% |
| ROCE % | - | -14.2% | -17.0% | -23.1% | -39.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 0.96% | 293.10K | $653.62K |
| 2 | Geode Capital Management, LLC | 0.76% | 231.02K | $515.17K |
| 3 | Vanguard Capital Management LLC | 0.66% | 200.97K | $448.17K |
| 4 | RBF Capital, LLC | 0.65% | 198.50K | $442.66K |
| 5 | Morgan Stanley | 0.54% | 165.55K | $369.19K |
| 6 | Millennium Management Llc | 0.35% | 105.54K | $235.35K |
| 7 | Bridgeway Capital Management, LLC | 0.32% | 98.45K | $219.54K |
| 8 | Vanguard Fiduciary Trust Co | 0.30% | 91.58K | $204.21K |
| 9 | Northern Trust Corporation | 0.25% | 76.09K | $169.67K |
| 10 | State Street Corporation | 0.24% | 73.01K | $162.80K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XBIT
XBIT — Frequently Asked Questions
What is the current share price of XBiotech Inc. (XBIT)?
As of 2026-08-02 19:16 PDT, XBiotech Inc. (XBIT) trades at $2.23 on NasdaqGS. Its 52-week range is $2.12 to $3.50.
What is the market capitalisation of XBIT?
XBiotech Inc. (XBIT) has a market capitalisation of $67.99M on NasdaqGS.
What is the P/E ratio of XBIT?
XBIT trades at a trailing price-to-earnings (P/E) ratio of -1.70. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 0.50.
What is the return on equity (ROE) of XBIT?
XBIT has a return on equity (ROE) of -25.93%. Its return on capital employed (ROCE) is -31.81%.
Is XBIT a good stock to buy?
This page provides a data-driven analysis of XBiotech Inc. (XBIT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.